Profound Medical Corp · TSX:PRN
Profound Medical — IPO Roadshow (July 2020)
20 slides from Profound Medical's IPO roadshow presentation, Jul 15, 2020
Slide 1: Corporate Presentation – Offering of Common Shares
NASDAQ: PROF TSX: PRN Corporate Presentation | July 15, 2020 – Offering of Common Shares © 2020 Profound Medical Corp. A final base shelf prospectus containing important information relating to the securities described in this document has been filed with the securities regulatory authorities in eac
Slide 2: Forward-Looking Information
2 Forward - Looking Information Certain statements in this presentation may contain certain information that is “forward - looking information” or “forward - looking statements” within the meaning of applicable securities laws with respect to Profound Medical Corp . (“Profound” or the “Company”) . S
Slide 3: Market & Industry Data; Use of Projections
3 Market & Industry Data Use of Projections Market data and industry forecasts contained in this presentation have been obtained from industry publications, various publicly available third - party sources and subscription - based reports as well as from management’s good faith estimates, which are
Slide 4: U.S. FDA Cleared, August 2019 – Ablation of Prostate Tissue
“My life should not have to change” U.S. FDA Cleared, August 2019 Ablation of Prostate Tissue 4
Slide 5: Anatomy & Current Landscape in the U.S. – Prostate Disease
5 Anatomy & Current Landscape in the United States (“U.S.”) Prostate Disease Figure: Kirby (1997) An Atlas of Prostatic Diseases, The Encyclopedia of Visual Medicine Series. 1 Based upon CMS data Common treatment options 1. Surgery to remove prostate 2. Radiation to kill it in place Common sides eff
Slide 6: Our Solution
6 Our Solution TULSA - PRO How we control Closed - loop Thermal Feedback Robotic closed loop temperature control to enable whole gland ablation of any size prostate Ablation using real time MRI imaging and thermometry Transurethral Directional Thermal Ultrasound How we ablate Real - time MRI Guidanc
Slide 7: Real-Time MRI Guidance: How we see & plan
7 Patient MRI Bore, Physicians Create 3D Treatment Plan Using Real - Time MRI Visualization TULSA - PRO Real - time MRI Guidance How we see & plan
Slide 8: Transurethral Directional Thermal Ultrasound: How we ablate
8 Transurethral Gentle Heating of Prostate to 55º C TULSA - PRO Sweeping ultrasound, continuous rotation Capable of treating both large and small prostate volumes Thermal protection of important anatomy Prostate Heating pattern Ultrasound applicator with individually controlled transducer elements E
Slide 9: System Components
9 System Components TULSA - PRO Disposables Capital System Endorectal Cooling Device Transurethral Ultrasound Applicator Robotic Positioning System Interface Box Energy System Real - Time TULSA Thermal Images Closed - loop MRI Console How we control Closed - loop Thermal Feedback
Slide 10: Pivotal Study of Whole-Gland Ablation in a Clinically-Significant Patient Population
10 Immediate Post PSA 6.0 ng/ml 3 - months Post PSA < 0.1 ng/ml 12 - months Post: 0.5 cc PSA < 0.1 ng/ml Screening: 58 cc PSA 5.5 ng/ml 10 Pivotal Study of Whole - Gland Ablation in a Clinically - Significant Patient Population TACT Clinical Trial Prostate volume significantly reduced: • Median pros
Slide 11: Safety & Patient Quality of Life
11 Adverse Events • No grade ≥ 4 adverse events • No intraoperative complications • No rectal injury, no rectal fistula • 7% of men experienced a serious adverse event, all resolved by 1 year Urinary Incontinence • No new onset between 1 and 2 years • 1% patients reported one or more leak per day, 7
Slide 12: Flexibility to Treat Different Types of Patients
12 Whole Gland Ablation Unique Flexibility Analogous to surgery and radiation Whole gland post radiation failure Malignant lesion with lower urinary tract symptoms Hemi - gland Benign large prostate with lower urinary tract symptoms Flexibility to Treat Different Types of Patients TULSA - PRO
Slide 13: U.S. Market Entrance Strategy
13 TULSA - PRO U.S. Market Entrance Strategy • TACT clinical data presented at >10 conferences (AUA, EAU, RSNA) • TULSA - PRO and TACT clinical data presentations • Low - cost / high - impact patient awareness initiatives • TULSA patient website with center locator • Imaging centers • Urology practi
Slide 14: Recurring Revenue-Only: Commercial Imaging Centers
14 Recurring Revenue - Only Commercial Imaging Centers • 8,000 - 10,000 imaging centers in U.S.; 40% owned by private equity or public companies • Growing presence in urology due to MRI diagnostics, MRI - guided biopsy, MRI - guided follow - up • Centers provide: - Service - Technology - In - house
Slide 15: Capital + Consumables Sales: Centers of Excellence
15 Capital + Consumables Sales Centers of Excellence • Includes many of the TACT study sites • Will likely be relatively low volume while TULSA is a patient self - pay procedure • Best positioned to help drive long - term adoption by: - Participate in additional trials designed to support reimbursem
Slide 16: Growing Resource for Prostate Patients
16 Growing Resource for Prostate Patients New TULSA - PRO Patient Website TULSA Center Locator Page Detailed Information to Help Patients Understand Their Options Contact Forms to Reach Out to Each Center Directly Patient Testimonials 16
Slide 17: Longer Term: Building an Incision- & Radiation-Free Ablative Therapeutic Platform
Longer Term Building an Incision - & Radiation - Free Ablative Therapeutic Platform Oncology, Highly Symptomatic Chronic Diseases 17
Slide 18: Current Approvals
18 Current Approvals Europe: CE Marked China: CNMPA Approved Over 200 Publications from leading U.S. & European clinicians and hospitals SONALLEVE • Uterine Fibroid Treatment • Pain Management • Pediatric Bone • Hyperthermia • Abdominal Cancer
Slide 19: In Summary
19 In Summary Business Model Designed to be Capital Efficient • TULSA - PRO: focus on U.S. • Sonalleve : focus on Asia with larger distribution partner Future Investments • Strategically expand U.S. - based sales team, continue work with MRI partners • Additional clinical trials for TULSA - PRO for
Slide 20: PROFGGND
PROFGGND